This article is more than 5 years old. Information may no longer be current.

VIDEO: ASCO features pivotal data readouts from AstraZeneca portfolio

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Andrew Coop, vice president of U.S. medical affairs for oncology at AstraZeneca, spoke with HemOnc Today at ASCO Annual Meeting about advances in the company’s oncology portfolio.

At ASCO, researchers presented data from a study designed to compare the PARP inhibitor olaparib (Lynparza, AstraZeneca) with a standard of care for patients with metastatic, castration-resistant prostate cancer.

Other studies assessed moxetumomab pasudotox (MedImmune/AstraZeneca) — an investigational anti-CD22 recombinant immunotoxin — for patients with relapsed/refractory hairy cell leukemia, as well as selumetinib (AZD6244) for children with neurofibromatosis.